non-Hodgkin lymphoma	is a	cancer
diffuse large B-cell lymphoma	is a	non-Hodgkin lymphoma
follicular lymphoma	is a	non-Hodgkin lymphoma
mantle cell lymphoma	is a	non-Hodgkin lymphoma
burkitt lymphoma	is a	non-Hodgkin lymphoma
marginal zone lymphoma	is a	non-Hodgkin lymphoma
extranodal marginal zone lymphoma	is a	non-Hodgkin lymphoma
primary mediastinal large B-cell lymphoma	is a	non-Hodgkin lymphoma
T-cell lymphoma	is a	non-Hodgkin lymphoma
diffuse large B-cell lymphoma	originates from	B cells
follicular lymphoma	originates from	germinal center B cells
mantle cell lymphoma	originates from	mantle zone B cells
burkitt lymphoma	originates from	germinal center B cells
marginal zone lymphoma	originates from	marginal zone B cells
extranodal marginal zone lymphoma	originates from	marginal zone B cells
non-Hodgkin lymphoma	associated with	immunodeficiency
non-Hodgkin lymphoma	associated with	HIV infection
non-Hodgkin lymphoma	associated with	autoimmune disease
non-Hodgkin lymphoma	associated with	Epstein-Barr virus
non-Hodgkin lymphoma	associated with	hepatitis C virus
non-Hodgkin lymphoma	risk factors	older age
non-Hodgkin lymphoma	risk factors	male sex
lymph node biopsy	used for	diagnosis
immunohistochemistry	used for	diagnosis of non-Hodgkin lymphoma
immunohistochemistry	used for	classification of non-Hodgkin lymphoma
flow cytometry	used for	classification of non-Hodgkin lymphoma
bone marrow biopsy	used for	staging of non-Hodgkin lymphoma
PET-CT	used for	staging of non-Hodgkin lymphoma
Ann Arbor staging	used for	non-Hodgkin lymphoma
Ann Arbor staging	defines	disease extent
non-Hodgkin lymphoma	treated with	chemotherapy
non-Hodgkin lymphoma	treated with	rituximab
non-Hodgkin lymphoma	treated with	radiotherapy
diffuse large B-cell lymphoma	treated with	R-CHOP
follicular lymphoma	treated with	rituximab
diffuse large B-cell lymphoma	treated with	autologous stem cell transplantation
diffuse large B-cell lymphoma	treated with	CAR T-cell therapy
non-Hodgkin lymphoma	treated with	targeted therapy
non-Hodgkin lymphoma	treated with	hematopoietic stem cell transplantation
non-Hodgkin lymphoma	treated with	radiochemotherapy
rituximab	causes	B-cell depletion
rituximab	enhances	antibody-dependent cellular cytotoxicity
cyclophosphamide	part of	CHOP regimen
doxorubicin	part of	CHOP regimen
vincristine	part of	CHOP regimen
prednisone	part of	CHOP regimen
R-CHOP	associated with	complete response rate
R-CHOP	associated with	overall survival
R-CHOP	associated with	neutropenia
R-CHOP	associated with	neuropathy
CAR T-cell therapy	used for	relapsed non-Hodgkin lymphoma
intrathecal methotrexate	used for	CNS prophylaxis
ibrutinib	used for	mantle cell lymphoma
ibrutinib	used for	CLL/SLL
bendamustine	used for	indolent non-Hodgkin lymphoma
rituximab	used for	CD20-positive lymphoma
bortezomib	used for	mantle cell lymphoma
lenalidomide	used for	follicular lymphoma
dexamethasone	used for	NHL therapy
etoposide	used for	NHL chemotherapy
bleomycin	used for	NHL chemotherapy
cyclophosphamide	used for	NHL chemotherapy
maintenance rituximab	used for	long-term NHL control
auto SCT	used for	consolidation in NHL
intravenous immunoglobulin	used for	supportive care in NHL
paraneoplastic syndrome	seen with	NHL
Hodgkin lymphoma	is different from	non-Hodgkin lymphoma
EBV-associated NHL	is a subset of	non-Hodgkin lymphoma
immunodeficiency-associated NHL	is a subset of	non-Hodgkin lymphoma
limited stage NHL	tends to have	better prognosis
advanced stage NHL	tends to have	poorer prognosis
double-hit lymphoma	is a	high-grade NHL
double-hit lymphoma	characterized by	MYC and BCL2 rearrangements
indolent NHL	shows	slow progression
high-grade NHL	shows	rapid progression
B symptoms	present with	NHL
bone marrow involvement	indicates	systemic disease
peripheral blood involvement	indicates	dissemination
CNS involvement	indicates	CNS disease
CNS prophylaxis	recommended for	high-risk NHL
Hodgkin lymphoma	is distinguished from	non-Hodgkin lymphoma
EBV-associated NHL	is a subset of	non-Hodgkin lymphoma
immunodeficiency-associated NHL	is a subset of	non-Hodgkin lymphoma
overexpression of BCL2	observed in	follicular lymphoma
gene expression profiling	informs	classification of NHL
cytogenetics	informs	prognosis of NHL
CD20 expression	influences	rituximab efficacy
myc rearrangement	associated with	Burkitt lymphoma
BCL2 rearrangements	seen in	follicular lymphoma
Ki-67 index	predicts	proliferative activity
t(14;18) translocation	characteristic of	follicular lymphoma
B symptoms	define	clinical presentation
staging	informs	prognosis
maxillary involvement	rare in	non-Hodgkin lymphoma
testicular involvement	occurs in	non-Hodgkin lymphoma
extranodal involvement	common in	non-Hodgkin lymphoma
gastric MALT lymphoma	arises in	stomach
overexpression of BCL2	observed in	follicular lymphoma
CAR T-cell therapy	associated with	cytokine release syndrome
non-Hodgkin lymphoma	screened by	whole-body imaging
